Busulfanis used in preparative regimens prior to hematopoietic stem cell transplantation in pediatric patients. There is significant interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. To date, only polymorphisms in genes encoding for glutathione-S-transferases were studied, but could only explain a small portion of the variability in PK. In this study we investigate the effect of seven genetic markers on busulfan clearance and the effect of ontogenesis on these genetic variants in a pediatric population. In an earlier study of our group seven genetic markers in GSTA1, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8
AbstrAct
Busulfanis used in preparative regimens prior to hematopoietic stem cell transplantation in pediatric patients. There is significant interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. To date, only polymorphisms in genes encoding for glutathione-S-transferases were studied, but could only explain a small portion of the variability in PK. In this study we investigate the effect of seven genetic markers on busulfan clearance and the effect of ontogenesis on these genetic variants in a pediatric population. In an earlier study of our group seven genetic markers in GSTA1, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8
were associated with busulfan clearance in adult patients. Eighty four pediatric patients were genotyped for these markers and genotype was associated with busulfan clearance. GSTA1
and CYP39A1 were found to be associated with busulfan clearance. When combined, the two haplotypes explained 17% of the variability in busulfan clearance. Furthermore, the effect of GSTA1 haplotype on clearance was dependent on age.
IntroductIon
Busulfan is an alkylating agent commonly used in high doses in conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients.
Busulfan has a narrow therapeutic index and its exposure is related to clinical outcome. Indeed, an increased risk for busulfan toxicity such as (hepatic) sinusoidal obstruction syndrome and mucositis are related to high busulfan exposure whereas rejection of the graft and disease recurrence is related to low busulfan exposure. [1] [2] [3] [4] Furthermore, interpatient variability in busulfan pharmacokinetics (PK) is considerable. Even when busulfan is administered intravenously, and thus excluding potential variation in absorption, interpatient variability in exposure remains between 20-30%. 5, 6 To limit variation in busulfan exposure and to optimize clinical outcome, 7 therapeutic drug monitoring is often applied in the clinical setting and population PK models have been developed. 5, 8 Furthermore, pharmacodynamics of busulfan differs based on the conditioning regimen prior to stem cell transplantation, the age of the patient and the recipients underlying disease. 9 Variability in busulfan clearance could possibly be explained by genetic variation in genes involved in the PK of busulfan. A tagging SNP (rs3957357, -69C/T) in a haplotype of the gene coding for GSTA1, an enzyme predominantly involved in busulfan metabolism, was found to be associated with busulfan clearance in earlier studies in adult populations. 10, 11 The percentage of variability in busulfan PK explained by genetic variation in GSTA1 differs per study, possibly owing to differences in ethnicity of the studied population or administration route in the different studies (oral versus intravenous administration of busulfan).
In pediatric patients the contribution of rs3957357 on busulfan PK is not as apparent as in adults: studies showed conflicting results for the effect of the GSTA1 haplotype on busulfan PK. [12] [13] [14] [15] This could be owing to other factors having a more profound effect on busulfan clearance in pediatric patients, such as bodyweight. In the pediatric population variation in bodyweight is much larger than in adults and it is known that busulfan clearance is significantly related to bodyweight in children. Furthermore, developmental changes affect PK pathways in young children. 16 Also the role of pharmacogenetics could be influenced by ontogenesis in young children. To date, studies looking for pharmacogenetic biomarkers related to busulfan PK have been limited by a candidate gene approach. In a recent study of ten Brink et al.
17
, the Drug Metabolizing Enzymes and Transporters (DMET) genotyping array (Affymetrix) was used to interrogate 1936 genetic markers in 225 genes involved in drug transport and metabolism in an adult population. Through systematic screening, seven potential genetic markers in six genes were identified. The identified markers were located in GSTA5, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8.
However, these results cannot be directly extrapolated to a pediatric population, since other factors such as ontogenesis or bodyweight can have a pronounced effect on busulfan PK. Therefore, the aim of the current study is to investigate the effect of seven genetic markers on busulfan clearance and the effect of ontogenesis on these genetic variants in the pediatric population.
MAterIAls And Methods

Patient characteristics
In this retrospective study, pediatric patients (≤ 18 years) receiving busulfan conditioning prior 
busulfan pharmacokinetics
Busulfan was administered in a 3 h infusion. Serum drug level measurements were collected at 4, 5 and 7 h after the start of busulfan infusion on the first day of treatment as part of routine patient care. A validated limited sampling model was used to limit the amount of samples necessary to calculate busulfan clearance and AUC. 8 Busulfan concentrations were analyzed in serum by a validated high-performance liquid chromatographic assay involving precolumnderivatization, liquid/liquid extraction and UV detection, previously described by our group. 18 Briefly, the limit of quantification was 30 μg/L and precision at 200 and 1500 μg/L was 3.5 and 0.8%, respectively. Individual PK parameters were calculated using a one-compartment population PK model for busulfan with linear elimi nation, developed in MW/Pharm version 3.6 (Mediware, Groningen, The Netherlands). 18, 19 The calculated mean population PK parameters, clearance and half-life, were individualized according to the maximum a posteriori Bayesian fitting method. 20 Exposure (AUC) was calculated by dividing the busulfan dose by estimated busulfan clear ance and was used to individualize busulfan dosing after the first dose. Clearance was adjusted to body surface area (BSA), since BSA describes busulfan clearance in children well.
21,22
Genotyping and haplotype estimation
Patients were genotyped for the seven potential genetic markers, in GSTA5, ABCB4, CYP39A1, CYP2C219, SLC7A8 and SLC22A4, previously identified by our group. 17 However, post hoc analysis revealed that GSTA5 is in linkage with GSTA1, which is the functionally active gene in humans. Therefore, we included GSTA1 (rs3957357) instead of GSTA5. Nine SNPs were analyzed in GSTA1 (rs3957357), ABCB4 (rs2109505 and rs45595532), CYP39A1 (rs9381468, rs953062 and were analyzed with LightScanner® Software using Call-IT 2.0. The GSTA1 SNP (rs3957357) was genotyped by pyrosequencing 13 (Qiagen, Venlo, The Netherlands).
As a quality control 10% of samples were genotyped in duplicate. SNPs with a call rate < 0.95
were removed from the analysis. Tradi tional Sanger sequencing was used to confirm HRM results for each SNP.
SNPs in CYP39A1 (rs9381468 and rs953062) and ABCB4 (rs2109505 and rs45595532) were included in the analysis as haplotypes. For each patient, haplotypes were estimated and haplotype Rh 2 was calculated using gPlink. 23 Haplotypes with Rh 2 > 0.95 were considered present.
statistical analysis
The primary end point of the study was the associations of each of the genetic markers with busulfan clearance. This was tested by univariate linear regression analysis with the SNP or haplotype in the additive model in PASW statistics, version 17.0.01 (SPSS Inc., IL, USA). Next, the significantly associated genetic markers were tested in a multivariate analysis. To explore the effect of ontogenesis in GSTA1, the effect of both haplotypes on busulfan clearance were studied in two different age groups (patients younger and older than 2 years). P-values less than 0.05 were considered statistically significant.
results description of the patient population
In this study, 84 patients receiving busulfan therapy were included. The mean age of patients was 6.1 years (± 5.4) and 69% of the patients were male. The mean busulfan clearance was 
Genotyping & association of genetic variants with busulfan clearance
The call rate of all eight SNPs determined with HRM was at least 98%. The call rate of the GSTA1 SNP with pyrosequencing was 96.4%. All SNPs showed Hardy-Weinberg equilibrium (p > 0.05).
Univariate regression analysis of the seven markers identified two markers being associated with busulfan clearance: GSTA1 (rs3957357; p = 0.004) and CYP39A1 (rs9381468 and rs953062; p = 0.011), see also ).
In patients with increasing numbers of variant alleles, the busulfan clearance was lower in comparison with patients with more wild-type alleles, see also 
effect of ontogenesis on GSTA1
Twenty children were younger than 2 years and 64 children were older than 2 years. In younger children it was noted that GSTA1 had a larger effect; explaining 20% of variability in clearance (p = 0.046) than in older children, explaining only 5.2% (p = 0.078), see also Figure 5 .2.
In the children younger than 2 years, the mean clearance was 6.9 ± 2. We performed a multivariate analysis taking GSTA1 genotype, CYP39A1 genotype, age (older or younger than 2 years) and underlying disease as covariates. Underlying disease was excluded as a covariate from the model and the two genotypes and age resulted in an explained variance of 21% (adjusted R 2 ) and p = 0.004. 
dIscussIon
In this study, GSTA1 and CYP39A1 were found to be associated with busulfan clearance. The involvement of GSTA1 in busulfan PK confirms earlier findings in pediatric patients; the involvement of a haplotype in CYP39A1 in busulfan PK is new. When combined, the two haplotypes explain 20% of the variability in busulfan clearance.
Busulfan is primarily metabolized by conjugation with glutathione, catalyzed by glutathione-
S-transferases (GSTs). GSTA1 is the pre dominant GST isoenzyme involved; GSTM1 and GSTP1
have 46% and 18% of the activity of GSTA1 in busulfan metabolism, respectively. 24 The effect of SNPs in genes encoding for GST enzymes on busulfan PK have been studied previously, both in adults and pediatric patients, leading to unclear results. The amount of variability in busulfan clearance explained by the most important SNP in GSTA1 (rs395735) differs per study, possibly due to ethnicity, busulfan route of administration (oral versus iv.) and age differences in the studied populations. Especially in the pediatric population, the role of the GSTA1 haplotype in busulfan PK is unclear.
The first study in pediatric patients, carried out by Johnson et al., showed that children who were heterozygous or homozygous for the GSTA1*B haplotype (regardless of age) exhibited a 30% decrease in busulfan clearance. 12 We also investigated the effect of SNPs in different GST genes (GSTA1, GSTM1, GSTP1 and GSTT1) and we did not find an association of the SNPs with busulfan clearance. 13 Also Ansari et al. did not find an effect of GSTA1 on busulfan clearance in pediatric patients, but showed lower busulfan clearances in patients with the GSTM1-null genotype. 14 Gaziev et al. studied the effect of the GSTA1 SNP in pediatric thalassemia patients showing 10% lower busulfan clearance in patients with the GSTA1*B variant. 15 An important difference between the positive and negative studies towards the effect of genetic variation in GSTA1 on busulfan clearance is the way in which clearance was expressed.
In the positive studies clearance was normalized for weight, which was not the case in the negative studies.
The effect of body size on busulfan clearance in pediatric patients has been studied extensively and could explain a major part of the variability. 25 In this study busulfan clearance was adjusted for BSA, as suggested by Trame et al. 21 and McCune et al. 22 We hypothesize that, when clearance is not normalized for body size (expressed as BSA, bodyweight or allometric scaled bodyweight), variability is much larger and the effect of body size surpasses the probably smaller effect of the genetic variants.
Several studies have identified factors affect ing the PK of busulfan; recipients underlying disease, age and concomitant administration of fludarabine. 22, 26, 27 McCune et al. demonstrated a larger variability in clearance in infants (i.e., ≤ 12 kg bodyweight) in comparison to older children, also when normalized for BSA. 22 This was also observed in our data; a variability in clearance of 36% was observed in younger children versus 25% in older children.
In our population, patients with different underlying diseases, age and cyclophosphamideand fludarabine-based conditioning regimens were included. We did not see a difference in clearance in patients with cyclophosphamide-based conditioning versus patients with fludarabine-based conditioning (p = 0.9).
Patients with immune deficiencies had an 18% lower clearance compared with patients with other underlying diseases (p = 0.02). Age also appeared to be related to clearance and clearance was 15% lower in patients younger than 2 years (p = 0.31). However, the proportion of patients with immune deficiencies was larger in patients younger than 2 years (p = 0.02) and in the multivariate analysis only age remained as an independent predictor of clearance.
Apart from inherited differences in enzyme function, developmental changes in enzyme function also play an important role in the metabolic capacity of pediatric patients. Ontogenesis in young children could influence the explanatory power of pharmacogenetic biomarkers affecting busulfan PK. Unfortunately there are no specific data on ontogenesis of GSTAs available. However, for most enzymes developmental changes in expression is complete in the first 2 years after birth. Therefore, we explored the potential role of ontogenesis on pharmacogenetic differences in GSTA1 by studying the effect of GSTA1 genotype in two different age groups (younger and older than 2 years of age). Our study shows for the first time an agedependent effect of genetic differences in GSTA1. The effect of GSTA1 on busulfan clearance was much stronger in younger children. This might be owing to an incomplete development of enzyme capacity in young children, resulting in a more pronounced effect of genetic variation on busulfan clearance.
This study revealed a potential role of the CYP39A1 haplotype in busulfan PK. The functional effects of the SNPs in the CYP39A1 haplotype are currently unknown and warrant further study.
Also, the role in busulfan metabolism needs clarification. Interestingly, the software of the DMET platform classifies both SNPs as being part of the CYP39A1 gene, but according to the NCBI SNP database, both SNPs are located in the SLC25A27 gene. In fact, the promoter region of CYP39A1 and the gene of SLC25A27 are overlapping.
CYP39A1 encodes for a member of the CYP450 superfamily of enzymes, and it is involved in the conversion of cholesterol to bile acids. The synthesis and excretion of bile acids comprise the major pathway of cholesterol catabolism in humans. The SLC25A27 gene, which encodes member 27 of the solute carrier 25 family, is also known as UPC4. These proteins are part of the family of mitochondrial anion carrier proteins and are involved in the transfer of anions from the inner to the outer mitochondrial membrane. 28 The effect of this identified haplotype should be further investigated.
The combined haplotypes in GSTA1 and CYP39A1 could explain 17% of the remaining variability in busulfan clearance. The clearance in patients who are homozygous for both variant haplotypes was 39% lower in comparison with wild-type patients. The effect of these two SNPs on busulfan clearance calls for further research into their relationship with clinical outcomes such as engraftment and toxicity.
Two haplotypes in CYP3391 and GSTA1 were found to be associated with busulfan clearance in pediatric patients. The CYP39A1 haplotype was not previously related with busulfan PK. The role of the haplotype in GSTA1 is in line with earlier findings. Furthermore, the effect of GSTA1
haplotype on clearance was dependent on age. In young children this haplotype explained 20% of the variability in busulfan clearance, in the older children GSTA1 explained 5.2% of the variability.
Busulfan is one of the cornerstones of conditioning regimens in HSCT in pediatric patients.
Busulfan dosing can be optimized by increasing our knowledge of the variables affecting busulfan PK, including the effect of pharmacogenetic markers. The effect of GSTA1 and CYP39A1 polymorphisms on busulfan-related treatment outcomes such as engraftment and toxicity should be investigated. Busulfan pharmacogenetics ultimately holds the potential to optimize conditioning of pediatric HSCT patients by decreasing toxicity and increasing efficacy.
